Loading
institutionsInstitution
Sheba Medical Center
Israel's largest hospital, whose cancer centre led the POLO trial of olaparib in pancreatic cancer and runs one of the world's few TIL therapy programmes.
Also called: Chaim Sheba Medical CenterTel HaShomerSheba Cancer Center
Overview
Sheba Medical Center at Tel HaShomer describes itself as the largest hospital in Israel and hosts the Jusidman Cancer Center. Talia Golan led the POLO trial that established maintenance olaparib for germline BRCA-mutated pancreatic cancer, the Ella Lemelbaum Institute for Immuno-Oncology under Jacob Schachter, Michal Besser and Gal Markel has treated melanoma patients with tumour-infiltrating lymphocytes since 2006, and the haematology division runs point-of-care CAR-T manufacturing. Sheba's ARC innovation centre and its large breast, gastrointestinal, thoracic and paediatric oncology services make it Israel's most active oncology trial site, and its Sackler-affiliated researchers publish widely on precision oncology.
Location
Ramat Gan, IL
Type
hospital · Tel Aviv University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#44 · 56 points (0 Newsweek + 0 NCI + 56 from 28 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Sheba Medical Center, including child institutions. 715 works · 9,094 citations · 65% open access · 14% clinical trials · 2% reviews.
Oncology works per year
1492022
1642023
1542024
1532025
952026
Most works
- Nir Horesh68 works
- Sameh Hany Emile60 works
- Steven D. Wexner58 works
- Talia Golan55 works
- Zoe Garoufalia55 works
- Roni Shouval46 works
- Elad Jacoby42 works
- Jair Bar40 works
- Rachel Gefen40 works
- Avichai Shimoni38 works
Most cited
- POLO trial and BRCA-mutated pancreatic cancer
- TIL therapy (Ella Lemelbaum Institute)
- CAR-T manufacturing
- ARC innovation centre
- Paediatric oncology
Eitan Friedman
Oncogeneticist, Meirav High Risk Clinic, Sheba Medical Center; professor, Gray Faculty of Medical and Health Sciences, Tel Aviv University
Cancer geneticsBRCA founder variantsNon-Ashkenazi Jewish and Arab cancer genetics
Mapped which inherited cancer variants recur in which Israeli communities, and showed that outside the Ashkenazi founder panel there is no shortcut: you have to sequence.
Gal Markel
Director, Skin Cancer and Melanoma Center, Davidoff Cancer Center, Rabin Medical Center; Gray Faculty of Medical and Health Sciences, Tel Aviv University
MelanomaTumour immunologyCheckpoint inhibitors
A tumour immunologist who helped build Israel's melanoma cell therapy programme at Sheba and now runs the melanoma centre at Davidoff, publishing what checkpoint drugs do outside the clean conditions of a trial.
Jacob Schachter
Director, Ella Lemelbaum Institute for Immuno-Oncology and Melanoma, Sheba Medical Center
MelanomaImmunotherapyAdoptive cell therapy
Built the melanoma and immunotherapy institute at Sheba that has been growing patients' own tumour-infiltrating lymphocytes and giving them back since 2006, more than a decade before any regulator approved the idea.
Michal Besser
Head of the Ella Lemelbaum Institute cell therapy laboratory, Sheba Medical Center; Gray Faculty of Medical and Health Sciences, Tel Aviv University
Tumour-infiltrating lymphocytesAdoptive cell therapyT-cell manufacturing
Runs the laboratory that actually grows the cells. Her papers are the reason anyone outside the United States believed a hospital could manufacture tumour-infiltrating lymphocytes reliably.
Talia Golan
Director, Pancreatic Cancer Center, Sheba Medical Center
Pancreatic cancerBRCA-associated cancerPARP inhibitors
Led POLO, the first biomarker-driven trial in pancreatic cancer, which brought olaparib to BRCA carriers.
Yitshak Kreiss
Director General
Hospital managementHealth innovationDisaster medicine
Director General of Sheba Medical Center since 2016, leading Israel's largest hospital and its cancer centre.
reviewInternational Journal of Cancer 20261 citation
Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium
The current honest statement of where early detection stands: no blood test is ready, and the research is about finding the threshold at which to operate.
observationalBritish Journal of Cancer 2014347 citations
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
The retrospective platinum signal that made platinum-based first-line chemotherapy the standard for BRCA carriers and set POLO's design of olaparib after platinum.
observationalProceedings of the National Academy of Sciences 2014changed practice256 citations
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2
This is the evidence base for offering an inherited-risk test to a whole population rather than to people who already look high risk. It is why Israel's health basket funds BRCA founder testing for every woman of Ashkenazi origin without a family history requirement, and it is quoted in every argument for doing the same elsewhere.
observationalClinical Cancer Research 2013326 citations
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies
It showed that a single academic centre outside the United States could run tumour-infiltrating lymphocyte therapy at scale and get durable remissions, and it quantified the attrition that intent-to-treat reporting exposes and single-arm treated-patient reporting hides.
Similar pages
- PersonZelig Eshhar
Shares Tel Aviv University, Tel Aviv Sourasky Medical Center, Weizmann Institute of Science, Manufacturing cost and time for living and radioactive medicines.
- TrialPOLO
Shares Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers, Talia Golan, PARP, PARP inhibitors.
- InstitutionIsrael Cancer Association
Shares Israel National Cancer Registry, Melanoma, HR-positive / HER2-negative breast cancer.
- TermFounder variant
Shares Eitan Friedman, Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2, BRCA1 / BRCA2 (HRD).
- TrialSOLO-1
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
- TrialOlympiAD
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
- PersonJonathan A. Ledermann
Shares PARP, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
- Key paperPOLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer
Shares Talia Golan, Olaparib, BRCA1 / BRCA2 (HRD), Pancreatic ductal adenocarcinoma.
cancers
fronts
technologies
targets
drugs
ApprovedSmall-molecule PARP inhibitor
Olaparib · Lynparza
companies
institutions
trials
people
bottlenecks
key papers
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapiesOverall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriersPancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortiumPopulation-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2